行情

ADAP

ADAP

Adaptimmune
NASDAQ

实时行情|Nasdaq Last Sale

1.220
-0.020
-1.61%
盘后: 1.290 +0.07 +5.74% 19:09 12/13 EST
开盘
1.260
昨收
1.240
最高
1.290
最低
1.170
成交量
28.15万
成交额
--
52周最高
6.31
52周最低
0.7090
市值
1.28亿
市盈率(TTM)
-0.8883
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADAP 新闻

  • Adaptimmune gets FDA designation to accelerate development of cancer therapy
  • American City Business Journals.12/03 19:20
  • Adaptimmune's ADP-A2M4 nabs RMAT tag for rare soft tissue cancer
  • Seeking Alpha - Article.12/03 17:31
  • Regenerative Medicine Advanced Therapy Designation Granted By FDA To Adaptimmune's ADP‑A2M4 For Treatment Of Synovial Sarcoma
  • Benzinga.12/03 13:33
  • Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADPA2M4 for the Treatment of Synovial Sarcoma
  • GlobeNewswire.12/03 13:30

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

ADAP 简况

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
展开

Webull提供Adaptimmune Therapeutics PLC - ADR的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。